Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Environmental and Molecular Mutagenesis|February 26, 1999
Predicting rodent carcinogenicity using potency measures of the in vitro sister chromatid exchange and chromosome aberration assaysJ S Schildcrout, B H Margolin, E Zeiger
Environmental and Molecular Mutagenesis|January 1, 1997
Predicting rodent carcinogenicity from mutagenic potency measured in the Ames Salmonella assayB A Fetterman, B S Kim, B H Margolin, et al.
Clinical Pharmacology and Therapeutics|November 21, 2013
Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testingS L Van Driest, Y Shi, E A Bowton, et al.
The American Journal of Cardiology|October 8, 1999
Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteriesJ M Miller, R Smalling, E M Ohman, et al.
The Pharmacogenomics Journal|August 12, 2015
Attitudes of clinicians following large-scale pharmacogenomics implementationJ F Peterson, J R Field, Y Shi, et al.
Clinical Pharmacology and Therapeutics|December 24, 2015
Physician response to implementation of genotype-tailored antiplatelet therapyJ F Peterson, J R Field, K M Unertl, et al.
Clinical Pharmacology and Therapeutics|June 29, 2012
Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotypingJ S Schildcrout, J C Denny, E Bowton, et al.
Clinical Pharmacology and Therapeutics|December 23, 2011
Predicting clopidogrel response using DNA samples linked to an electronic health recordJ T Delaney, A H Ramirez, E Bowton, et al.
Clinical Pharmacology and Therapeutics|January 17, 2017
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare SystemsJ A Luzum, R E Pakyz, A R Elsey, et al.
Pageof 1